- Home
- DV vs VERA Comparison
DV vs VERA Comparison
Compare DV & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- VERA
- Stock Information
- Founded
- DV 2008
- VERA 2016
- Country
- DV United States
- VERA United States
- Employees
- DV N/A
- VERA N/A
- Industry
- DV Computer Software: Prepackaged Software
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- DV Technology
- VERA Health Care
- Exchange
- DV Nasdaq
- VERA Nasdaq
- Market Cap
- DV 3.2B
- VERA 2.7B
- IPO Year
- DV 2021
- VERA 2021
- Fundamental
- Price
- DV $19.47
- VERA $33.37
- Analyst Decision
- DV Buy
- VERA Buy
- Analyst Count
- DV 20
- VERA 8
- Target Price
- DV $25.63
- VERA $63.50
- AVG Volume (30 Days)
- DV 1.8M
- VERA 749.7K
- Earning Date
- DV 02-27-2025
- VERA 11-07-2024
- Dividend Yield
- DV N/A
- VERA N/A
- EPS Growth
- DV 18.39
- VERA N/A
- EPS
- DV 0.38
- VERA N/A
- Revenue
- DV $638,459,000.00
- VERA N/A
- Revenue This Year
- DV $19.31
- VERA N/A
- Revenue Next Year
- DV $12.99
- VERA N/A
- P/E Ratio
- DV $51.45
- VERA N/A
- Revenue Growth
- DV 19.57
- VERA N/A
- 52 Week Low
- DV $16.12
- VERA $14.20
- 52 Week High
- DV $43.00
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- DV 48.56
- VERA 22.57
- Support Level
- DV $19.28
- VERA $31.77
- Resistance Level
- DV $19.86
- VERA $36.28
- Average True Range (ATR)
- DV 0.54
- VERA 2.18
- MACD
- DV -0.02
- VERA -0.86
- Stochastic Oscillator
- DV 25.31
- VERA 13.34
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. The DV Authentic Ad ensures that a digital ad was delivered in a brand-safe setting, completely viewable, by a real individual, and in the expected geography, is one of its solutions. It generates revenues from its advertisement customers by charging a Measured Transaction Fee on the volume of Media Transactions Measured on the software platform.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.